GlassScriptPhysician profile
Pavlina Suchanova
NPI 1750603700
$67,697.25
in general payments reported to CMS, 2019-2025
27 companies · $34K in 2025
The $34K reported for 2025 was more than what 99% of Otolaryngology providers received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,171 · 2020: $1,601 · 2021: $2,797 · 2022: $9,236 · 2023: $11K · 2024: $5,267 · 2025: $34K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $24K · Consulting Fee: $17K · Food and Beverage: $6,817 · Travel and Lodging: $3,790.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $23,705.00 |
| Consulting Fee | $16,579.45 |
| Food and Beverage | $6,817.37 |
| Travel and Lodging | $3,790.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Optinose US, INC. | $34,155.31 | 2019-2025 | |
| Aerin Medical INC. | $22,567.55 | 2019-2025 | |
| Stryker Corporation | $4,250.99 | 2019-2024 | Scopis Ent, Audion Et Dilation System, Xpress Ent Dilation System |
| Intersect Ent, INC. | $2,542.91 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $782.37 | 2019-2025 | Dupixent |
| Genzyme Corporation | $728.34 | 2019-2025 | |
| Medtronic, INC. | $528.25 | 2022-2025 | Sinuva, Propel, Novapak |
| Glaxosmithkline, LLC. | $503.66 | 2021-2025 | Nucala |
| Acclarent, INC | $264.08 | 2019-2023 | Trudi Nav Cable |
| Ars Pharmaceuticals Operations, INC. | $222.92 | 2025 | Neffy |
| Hikma Pharmaceuticals USA | $179.58 | 2022-2025 | Ryaltris |
| Grifols USA, LLC | $169.28 | 2021-2025 | Xembify |
| Alk-Abello, INC | $168.88 | 2021-2022 | |
| Arrinex, INC. | $131.44 | 2019 | |
| Csl Behring | $82.63 | 2024-2025 | Hizentra |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic USA, INC. | $64.06 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $57.24 | 2023-2025 | Takhzyro, Cuvitru |
| Paratek Pharmaceuticals, INC. | $49.57 | 2025 | Xhance |
| Octapharma USA, INC. | $49.23 | 2021 | |
| Inspire Medical Systems, INC. | $40.31 | 2023 | Inspire |
| Kaleo, INC. | $38.52 | 2023 | Auvi-Q |
| Novartis Pharmaceuticals Corporation | $28.46 | 2019 | |
| Amgen INC. | $23.12 | 2025 | Tavneos |
| Aimmune Therapeutics, INC. | $21.11 | 2021 | |
| Olympus America INC. | $18.87 | 2024 | |
| Ascendis Pharma Endocrinology INC | $14.84 | 2025 | Yorvipath |
| Arbor Pharmaceuticals, INC. | $13.73 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pavlina Suchanova listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.